DeepTek.ai secures US FDA clearance for its groundbreaking Chest X-ray AI solution

DeepTek.ai, the leading medical imaging AI company in India has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution – CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorizes, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations.

Unlike traditional point AI solutions identifying a specific pathology, DeepTek’s Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It’s compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful.

This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasizes the role of AI in addressing this challenge.

Dr. Amit Kharat, Co-Founder of DeepTek.ai, quoted “DeepTek CXR Analyzer v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50%. With FDA clearance, we’re not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we’re unlocking a world of possibilities for improved outcomes across various medical specialties.”

DeepTek’s AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers are using DeepTek’s AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened using DeepTek’s Chest X-Ray Analyzer for tuberculosis screening. In Singapore, DeepTek’s US FDA approved Platform – Augmento has been deployed as the National Radiology AI platform, boosting productivity and quality of care across all public hospitals.

With its operations in Pune; DeepTek has about 200 members and has partners like TATA Capital, NTT DATA Japan and Shimadzu Asia Pacific.